sunitinib,BEZUCLASTINIB
pfizer,Cogent Biosciences
['sunitinib', '#gi']
today at #asco23 we announced positive lead-in data from our ongoing phase 3 peak trial with bezuclastinib + sunitinib in #gist. read more here and join the webcast on monday at 8am et. 
Precision therapeutics for genetically defined diseases